株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

住血吸虫症:パイプライン製品の分析

Schistosomiasis - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 251629
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
住血吸虫症:パイプライン製品の分析 Schistosomiasis - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 37 Pages
概要

住血吸虫症は、川や湖などの淡水に生息する寄生虫によって引き起こされる感染症の一種です。症候は、高熱、頭痛、咳、濃くて赤い炎症を起こして盛り上がった皮膚炎、腹痛、関節痛、筋肉痛などが見られます。

当レポートでは、住血吸虫症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

住血吸虫症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;S比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • BioDiem Ltd
  • Concert Pharmaceuticals, Inc.
  • Kancera AB
  • LondonPharma Ltd
  • Merck KGaA

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BDM-I
  • D-Praziquantel
  • 腸住血吸虫症 ワクチン
  • L-Praziquantel
  • 住血吸虫症向け小分子

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Table 1: Number of Products under Development for Schistosomiasis, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Universities/Institutes, H2 2019
  • Table 6: Number of Products by Stage and Target, H2 2019
  • Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 8: Number of Products by Stage and Route of Administration, H2 2019
  • Table 9: Number of Products by Stage and Molecule Type, H2 2019
  • Table 10: Schistosomiasis - Pipeline by Ebelle Pharmaceuticals Inc, H2 2019
  • Table 11: Schistosomiasis - Pipeline by IRBM Science Park SpA, H2 2019
  • Table 12: Schistosomiasis - Pipeline by Knight Therapeutics Inc, H2 2019
  • Table 13: Schistosomiasis - Pipeline by Merck KGaA, H2 2019
  • Table 14: Schistosomiasis - Pipeline by Pai Life Sciences Inc, H2 2019
  • Table 15: Schistosomiasis - Pipeline by Tongli Biomedical Co Ltd, H2 2019
  • Table 16: Schistosomiasis - Dormant Projects, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Schistosomiasis, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11546IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2019, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.

Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schistosomiasis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Schistosomiasis - Overview
  • Schistosomiasis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Schistosomiasis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Schistosomiasis - Companies Involved in Therapeutics Development
    • Ebelle Pharmaceuticals Inc
    • IRBM Science Park SpA
    • Knight Therapeutics Inc
    • Merck KGaA
    • Pai Life Sciences Inc
    • Tongli Biomedical Co Ltd
  • Schistosomiasis - Drug Profiles
    • EDE-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intestinal schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-Praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miltefosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Schistosomiasis - Dormant Projects
  • Schistosomiasis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 18, 2018: George Washington University: Schistosoma vaccine to enter phase Ib clinical trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top